Sign inJoin waitlistJoin the waitlist

Matthew Macaluso

Vice Chair of Clinical Affairs · University of Alabama Hospital

Credentials: · · · · ·

History

University of Alabama Hospital
Present
Depression and Suicide Center · University of Alabama Hospital
Present
UAB Depression and Suicide Center · University of Alabama Hospital
Present

Psychiatry
University of Kansas School of Medicine
2006–2010
Rowan University School of Osteopathic Medicine
2001–2005

Research

Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study
Journal of Psychiatric Research · 2019 · 225 citations
Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant…
Journal of Psychiatric Practice · 2015 · 155 citations
Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial
Translational Psychiatry · 2018 · 111 citations

Michael Thase
20 papers
Richard Shelton
20 papers
Sheldon Preskorn
18 papers
Charles DeBattista
14 papers
CC
Charles Conway
11 papers
Boadie Dunlop
10 papers
BF
Brent Forester
10 papers
JG
John Greden
10 papers
Sagar Parikh
10 papers
Anthony Rothschild
9 papers
Dan Iosifescu
9 papers
Manish Jha
9 papers

Clinical trials

Vagal Nerve Stimulation for Treatment Resistant Major Depression
Principal investigator · Completed
University of Alabama at Birmingham
2022–2024
Cannabidiol for Treatment Resistant Depression
Principal investigator · Withdrawn · Phase 4
University of Alabama at Birmingham
2021
Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
Principal investigator · Terminated · Phase 2
Massachusetts General Hospital
2013–2016
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
Site PI · Not yet recruiting · Phase 3
Eli Lilly and Company
2026–2029